Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.

Prchal M, Pilz A, Simma O, Lingnau K, von Gabain A, Strobl B, Müller M, Decker T.

Vaccine. 2009 Dec 30;27 Suppl 6:G17-20. doi: 10.1016/j.vaccine.2009.10.016. Review.

PMID:
20006134
2.

Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.

Stern BV, Boehm BO, Tary-Lehmann M.

J Immunol. 2002 Jun 15;168(12):6099-105.

3.

Immunological adjuvants efficiently induce antigen-specific T cell responses in old mice: implications for vaccine adjuvant development in aged individuals.

Ebhardt MB, Shive CL, Guardia R, Gapin L, Boehm BO, Forsthuber TG.

Cell Immunol. 2002 Jan;215(1):87-97.

PMID:
12142040
4.
5.

A myeloid cell population induced by Freund adjuvant suppresses T-cell-mediated antitumor immunity.

Wang Z, Jiang J, Li Z, Zhang J, Wang H, Qin Z.

J Immunother. 2010 Feb-Mar;33(2):167-77. doi: 10.1097/CJI.0b013e3181bed2ba.

PMID:
20145547
6.

Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes.

Lee IF, Qin H, Priatel JJ, Tan R.

Eur J Immunol. 2008 Jan;38(1):82-9.

7.

Endogenous immune response to glutamic acid decarboxylase (GAD67) in NOD mice is modulated by adjuvant immunotherapy.

Qin HY, Elliott JF, Lakey JR, Rajotte RV, Singh B.

J Autoimmun. 1998 Dec;11(6):591-601.

PMID:
9878081
8.
9.
10.

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garçon N, Leroux-Roels G.

Vaccine. 2008 Mar 4;26(10):1375-86. doi: 10.1016/j.vaccine.2007.12.038. Epub 2008 Jan 14.

PMID:
18272264
11.

Adjuvant activity of cytokines.

Tovey MG, Lallemand C.

Methods Mol Biol. 2010;626:287-309. doi: 10.1007/978-1-60761-585-9_19. Review.

PMID:
20099135
12.

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.

Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH.

J Immunol. 2007 Oct 15;179(8):5033-40.

13.

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

Borsutzky S, Fiorelli V, Ebensen T, Tripiciano A, Rharbaoui F, Scoglio A, Link C, Nappi F, Morr M, Buttó S, Cafaro A, Mühlradt PF, Ensoli B, Guzmán CA.

Eur J Immunol. 2003 Jun;33(6):1548-56.

14.

CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice.

Maletto B, Rópolo A, Morón V, Pistoresi-Palencia MC.

J Leukoc Biol. 2002 Sep;72(3):447-54.

PMID:
12223511
15.

Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

Wingender G, Garbi N, Schumak B, Jüngerkes F, Endl E, von Bubnoff D, Steitz J, Striegler J, Moldenhauer G, Tüting T, Heit A, Huster KM, Takikawa O, Akira S, Busch DH, Wagner H, Hämmerling GJ, Knolle PA, Limmer A.

Eur J Immunol. 2006 Jan;36(1):12-20.

17.

Type I interferons as vaccine adjuvants against infectious diseases and cancer.

Bracci L, La Sorsa V, Belardelli F, Proietti E.

Expert Rev Vaccines. 2008 Apr;7(3):373-81. doi: 10.1586/14760584.7.3.373. Review.

PMID:
18393607
18.

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J.

Clin Cancer Res. 1999 Oct;5(10):2756-65.

19.
20.

Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses.

Ke Y, Li Y, Kapp JA.

Eur J Immunol. 1995 Feb;25(2):549-53.

PMID:
7875219

Supplemental Content

Support Center